MX2017014300A - Inhibidores de histona deacetilasa y composiciones y metodos para el uso de los mismos. - Google Patents

Inhibidores de histona deacetilasa y composiciones y metodos para el uso de los mismos.

Info

Publication number
MX2017014300A
MX2017014300A MX2017014300A MX2017014300A MX2017014300A MX 2017014300 A MX2017014300 A MX 2017014300A MX 2017014300 A MX2017014300 A MX 2017014300A MX 2017014300 A MX2017014300 A MX 2017014300A MX 2017014300 A MX2017014300 A MX 2017014300A
Authority
MX
Mexico
Prior art keywords
compositions
methods
histone deacetylase
deacetylase inhibitors
inhibitors
Prior art date
Application number
MX2017014300A
Other languages
English (en)
Inventor
Dominguez Celia
A Luckhurst Christopher
J Stott Andrew
C Maillard Michel
F Haughan Alan
Van De Poël Amanda
A Saville-Stones Elizabeth
Wishart Grant
Wall Michael
Breccia Perla
E Jarvis Rebecca
Original Assignee
Chdi Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chdi Foundation Inc filed Critical Chdi Foundation Inc
Publication of MX2017014300A publication Critical patent/MX2017014300A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se proporcionan ciertos inhibidores de la histona deacetilasa (HDAC) de Fórmula (I), sus composiciones y los métodos de su uso. (ver Fórmula).
MX2017014300A 2015-05-07 2016-05-06 Inhibidores de histona deacetilasa y composiciones y metodos para el uso de los mismos. MX2017014300A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562158363P 2015-05-07 2015-05-07
PCT/US2016/031335 WO2016179554A1 (en) 2015-05-07 2016-05-06 Histone deacetylase inhibitors and compositions and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2017014300A true MX2017014300A (es) 2018-08-09

Family

ID=57218014

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017014300A MX2017014300A (es) 2015-05-07 2016-05-06 Inhibidores de histona deacetilasa y composiciones y metodos para el uso de los mismos.

Country Status (12)

Country Link
US (2) US10053434B2 (es)
EP (1) EP3291810B1 (es)
JP (1) JP6805172B2 (es)
KR (1) KR20180002729A (es)
CN (1) CN107735088B (es)
AU (1) AU2016258188B2 (es)
CA (1) CA2984618C (es)
EA (1) EA036965B1 (es)
HK (1) HK1252487A1 (es)
IL (1) IL255448B2 (es)
MX (1) MX2017014300A (es)
WO (1) WO2016179554A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2984621C (en) 2015-05-07 2023-09-26 Chdi Foundation, Inc. Histone deacetylase inhibitors and compositions and methods of use thereof
EP3291810B1 (en) * 2015-05-07 2022-08-10 CHDI Foundation, Inc. Histone deacetylase inhibitors and compositions and methods of use thereof
WO2018015447A1 (en) * 2016-07-22 2018-01-25 Syngenta Participations Ag Microbiocidal oxadiazole derivatives
WO2018165520A1 (en) 2017-03-10 2018-09-13 Vps-3, Inc. Metalloenzyme inhibitor compounds
CN109627207A (zh) * 2018-12-17 2019-04-16 天津药明康德新药开发有限公司 一种3-(二氟甲氧基)哌啶盐酸盐的制备方法
WO2022174193A1 (en) * 2021-02-15 2022-08-18 The Research Foundation For The State University Of New York Radiolabeled compositions and methods of use thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006061638A2 (en) 2004-12-10 2006-06-15 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Heterocycle derivatives as histone deacetylase (hdac) inhibitors
ES2560627T3 (es) 2010-01-13 2016-02-22 Tempero Pharmaceuticals, Inc. Compuestos y procedimientos para la inhibición de HDAC
WO2013006408A1 (en) 2011-07-01 2013-01-10 Tempero Pharmaceuticals, Inc. Compounds and methods
JP6047563B2 (ja) * 2011-07-08 2016-12-21 ノバルティス アーゲー 新規トリフルオロメチル−オキサジアゾール誘導体および疾患の治療におけるその使用
WO2013009830A1 (en) 2011-07-13 2013-01-17 Tempero Pharmaceuticals, Inc. Methods of treatment
WO2013009810A1 (en) 2011-07-13 2013-01-17 Tempero Pharmaceuticals, Inc. Methods of treatment
PL2750677T4 (pl) * 2011-08-30 2017-12-29 Chdi Foundation, Inc. Inhibitory 3-monooksygenazy kinureninowej, kompozycje farmaceutyczne i sposoby ich stosowania
WO2013066833A1 (en) * 2011-10-31 2013-05-10 Glaxosmithkline Llc Compounds and methods to inhibit histone deacetylase (hdac) enzymes
WO2013066835A2 (en) * 2011-10-31 2013-05-10 Glaxosmithkline Llc Compounds and methods
CA2856334A1 (en) * 2011-11-28 2013-06-06 Christina Hebach Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease
CN104244939A (zh) * 2012-04-05 2014-12-24 Chdi基金会股份有限公司 犬尿氨酸-3-单加氧酶抑制剂、其药物组合物及其使用方法
CA2984621C (en) 2015-05-07 2023-09-26 Chdi Foundation, Inc. Histone deacetylase inhibitors and compositions and methods of use thereof
EP3291810B1 (en) * 2015-05-07 2022-08-10 CHDI Foundation, Inc. Histone deacetylase inhibitors and compositions and methods of use thereof
MY197262A (en) 2015-07-27 2023-06-08 Chong Kun Dang Pharmaceutical Corp 1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
PT3328844T (pt) 2015-07-27 2020-03-04 Chong Kun Dang Pharmaceutical Corp Derivados de 1,3,4-oxadiazol sulfamida como inibidor de histona desacetilase 6 e composição farmacêutica compreendendo os mesmos
JP6491393B2 (ja) 2015-08-04 2019-03-27 チョン クン ダン ファーマシューティカル コーポレーション ヒストン脱アセチル化酵素６阻害剤としての１，３，４−オキサジアゾール誘導体化合物及びこれを含有する薬剤学的組成物

Also Published As

Publication number Publication date
AU2016258188A1 (en) 2017-11-23
CN107735088B (zh) 2021-11-02
US20160326124A1 (en) 2016-11-10
EP3291810A1 (en) 2018-03-14
IL255448B2 (en) 2023-07-01
KR20180002729A (ko) 2018-01-08
CA2984618C (en) 2024-01-09
IL255448A0 (en) 2017-12-31
EA201792247A1 (ru) 2018-06-29
JP6805172B2 (ja) 2020-12-23
JP2018515489A (ja) 2018-06-14
EP3291810B1 (en) 2022-08-10
BR112017023711A2 (pt) 2018-07-17
CN107735088A (zh) 2018-02-23
HK1252487A1 (zh) 2019-05-24
US10053434B2 (en) 2018-08-21
IL255448B1 (en) 2023-03-01
EP3291810A4 (en) 2018-11-07
US20190202795A1 (en) 2019-07-04
AU2016258188B2 (en) 2021-08-26
CA2984618A1 (en) 2016-11-10
EA036965B1 (ru) 2021-01-20
WO2016179554A1 (en) 2016-11-10

Similar Documents

Publication Publication Date Title
MX2017014299A (es) Inhibidores de histona deacetilasa y composiciones y metodos para el uso de los mismos.
PH12017500509A1 (en) Benzyl substituted indazoles as bub1 inhibitors
MX2022004304A (es) Agentes inductores de apoptosis.
MX2016015743A (es) Compuestos de ciclopropilamina como inhibidores de histona demetilasa.
MX2016003843A (es) Inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos.
LT3319959T (lt) Histono deacetilazės hetero-halogeno inhibitoriai
MX2017014300A (es) Inhibidores de histona deacetilasa y composiciones y metodos para el uso de los mismos.
MX2020005213A (es) Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno (mk2) y sus usos.
EP3166603A4 (en) Treatment of leukemia with histone deacetylase inhibitors
PH12015500069A1 (en) Histone deacetylase inhibitors and compositions and methods of use thereof
IL249339A0 (en) Histone deacetylase inhibitors and compositions and methods of using them
EA201890364A1 (ru) СОЕДИНЕНИЯ, ПРИГОДНЫЕ ДЛЯ ИНГИБИРОВАНИЯ ROR-ГАММА-t
NZ711585A (en) Hdac inhibitors
PH12017501897A1 (en) 2-thiopyrimidinones
TW201613892A (en) Forms and compositions of an ERK inhibitor
EP3383494A4 (en) Histone deacetylase INHIBITORS